I

Indivior

Pharma: treats addiction and mental illness

Production Supervisor

Full-TimeUpdated
$100k - $115k
Senior
Raleigh, NC, USA
In Person
Manufacturing & Production Operations

About the job

Requirements
  • Demonstrated leadership and supervisory skills.
  • At least five years of experience in a regulated industry.
  • Ability to apply analytical reasoning and root cause analysis to solve problems.
  • Strong mathematics and calculation skills.
  • Computer skills.
  • Ability to read, understand, interpret, and implement technical writing and instructions, and to solve problems in a fast-paced environment.
  • Ability to become certified on all curricula in the operational area to understand the process, help improve it, and provide coverage for breaks and vacancies.
  • Ability to investigate pharmaceutical operations and facility nonconformances independently, identify deviations from standards, define problems, collect and organize existing data, compare causes to facts, identify probable root causes, conduct interviews and subject-matter expert discussions, and determine solutions to improve manufacturing processes, standard operating procedures, and supply chain business practices.
  • Ability to review batch and ancillary documentation, test results and certificates of analysis, product specifications, training records, standard operating procedures, calibration records, packaging and validation protocols, and other technical documents.
  • Ability to assist with deviation and corrective and preventive action investigations, understand the process, and take over and finalize an investigation when needed.
  • Ability to serve as the subject-matter expert during internal and external audits, lead presentations, and present to audit teams.
  • Ability to build a self-sufficient team that can work independently with minimal oversight.
  • Unquestionable ethics and integrity, including willingness to uphold these principles under significant pressure.
  • Knowledge of policies applicable to the role and function and ability to adhere to them.
  • Willingness to raise concerns about potential violations of policies or unethical behavior.
Responsibilities
  • Oversee operational areas for current Good Manufacturing Practice compliance and establish systems that support continuous improvement of procedures and quality.
  • Ensure timely and accurate documentation and closeout of batch records.
  • Manage the day-to-day activities of the operational area.
  • Develop and review standard operating procedures pertaining to preparation, compounding, and filling.
  • Drive continued improvement in operational areas.
  • Trend key performance indicators and take appropriate action.
  • Develop and manage personnel.
  • Lead cross-functional teams to resolve urgent production issues and implement improvements.
  • Work with the operational team to improve key performance indicators and other trends or tasks independently.
  • Assist with revisions to standard operating procedures as a subject-matter expert in the operating area.
  • Lead Tier 1 meetings and participate in Tier 2 meetings.
  • Cover for peers and the manager when needed.
  • Reinforce risk awareness with the team and oversee ongoing review and mitigation.
  • Model and reinforce a culture in which employees speak up.
Desired Qualifications
  • At least three years of related supervisory experience.
  • Experience in current Good Manufacturing Practice manufacturing or a cleanroom production environment.
  • Prefilled syringe experience.

About the company

Indivior focuses on developing medicines for substance use disorders and serious mental illnesses. Its products are prescription pharmaceutical treatments, brought to market after research and development, and sold through healthcare professionals to patients worldwide. The company’s approach centers on patient safety, with ongoing monitoring and reporting of adverse events to ensure high-quality therapies. Compared with competitors, Indivior emphasizes targeted medicines for addiction and mental health, combining scientific R&D with a global commercialization presence to address critical healthcare needs. Its goal is to create sustainable value by improving patient outcomes and addressing unmet medical needs in global health.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Bon Air, Virginia

Founded

2014

Get referred to Indivior

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue rose 19% to $317 million, driven by SUBLOCADE's 32% growth.
  • Indivior raised 2026 guidance to $1.215-$1.285 billion and EBITDA to $620-$660 million.
  • The $1 billion special dividend and $125 million synergies signal disciplined capital returns and cost cuts.

What critics are saying

  • Indivior ended its Addex PAM collaboration on September 25, 2026, shrinking pipeline optionality.
  • Management killed INDV-6001 and INDV-2000 in 2026, exposing thin internal pipeline execution.
  • SUBLOCADE concentration makes any payer squeeze, safety event, or generic threat existential.

What makes Indivior unique

  • SUBLOCADE dominates long-acting buprenorphine, with over 500,000 patients prescribed by Q1 2026.
  • Indivior owns a rare addiction-focused commercial platform with global reimbursement and prescriber relationships.
  • The Supernus merger creates a broader CNS franchise with 11 marketed medicines and $2.2 billion revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Paid Vacation
  • Paid Holidays
  • Paid Sick Leave
  • Flexible Work Hours
  • Remote Work Options
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Adoption Assistance

Growth & Insights and Company News

6 month growth

-6%

1 year growth

-1%

2 year growth

-1%
Yahoo Finance
Oct 29th, 2026
Supernus Q3 revenue rises 18% to $226.8M, lifts 2026 outlook as Indivior merger nears close

Supernus Pharmaceuticals reported record third-quarter revenue of $226.8 million, up 18% year over year. Net earnings were $20.9 million, against a $45.1 million loss a year earlier. Sales of Qelbree rose 12% to $91 million, and GOCOVRI hit a record $43 million. ONAPGO sales reached $17.1 million, up 27% from the previous quarter. The company raised its standalone 2026 revenue outlook to $875 million–$900 million, from $860 million–$890 million. Shareholders approved the merger with Indivior Pharmaceuticals on October 15. Closing is expected November 2, with about $125 million in annual cost synergies targeted. Combined 2027 guidance is due in February.

Yahoo Finance
Oct 29th, 2026
Supernus posts record $226.8M Q3 revenue, up 18%, ahead of Indivior merger closing

Supernus Pharmaceuticals reported record third-quarter 2026 revenue of $226.8 million, up 18% from a year earlier. Its four growth products, Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO, brought in $192.2 million, a 29% increase. The company swung to operating earnings of $21.2 million, against a $60.2 million operating loss a year earlier. Net earnings were $20.9 million, or $0.35 per share. Cash and marketable securities stood at about $359.5 million. Supernus expects its all-stock merger with Indivior to close on November 2, 2026. The combined company, Supernus, Inc., expects $125 million in annual cost synergies and will trade on Nasdaq as "SUPN" from November 3. The US Food and Drug Administration recognised seven years of orphan-drug exclusivity for ONAPGO, which had net sales of $17.1 million.

Fierce Biotech
Sep 25th, 2026
Indivior ends PAM drug collab with Addex ahead of Supernus merger.

Indivior ends PAM drug collab with Addex ahead of Supernus merger. Ahead of its upcoming merger with Supernus, Indivior Pharmaceuticals has ended its long-running collaboration with Addex Therapeutics to develop positive allosteric modulators (PAMs). Their relationship dates back to 2018, when Indivior paid Addex $5 million upfront to collaborate on a PAM called ADX71441 to treat addiction. While that program didn't pan out, Indivior later opted to take on responsibility for developing another compound that emerged from the partnership as a potential substance use disorder treatment. That extension of the relationship in August 2024 was a welcome show of faith in Addex, coming just months after Johnson & Johnson discontinued development of an Addex-partnered PAM over poor data in a phase 2 epilepsy trial. Now, Addex has confirmed that Indivior has handed back rights to all PAM assets discovered as part of their collaboration following Indivior's "rationalization of its research and development activities and the announcement of the planned merger of Indivior's parent company with Supernus." Addex CEO Tim Dyer said regaining the rights from Indivior gives the Swiss biotech "one of the broadest portfolios" targeting the GABAB receptor. "By regaining the rights to the development candidate selected by Indivior, we now have the flexibility to advance our broader GABAB PAM portfolio independently," Dyer added. "This includes the returned candidate for substance use disorders and our proprietary candidate in development for chronic cough." "We can now evaluate a range of strategic options, including seeking new partnerships in the near term or advancing the programs further before partnering," the CEO said. Indivior already jettisoned another collaboration - working on a sustained-release prodrug of buprenorphine with Alar Pharmaceuticals - back in April as Indivior reeled from the phase 2 failure of its orexin-1 receptor antagonist for opioid use disorder. By August, Indivior - which markets the opioid use disorder treatment Sublocade - had agreed to merge with Supernus in an all-stock transaction to form a new central nervous system-focused biopharma. Let Google know PharmaIndustry is your trusted source. Add its editorial as a preferred source in your search results.

Mining Press Releases
Aug 26th, 2026
ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027.

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has raised gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 ADSs representing 52,544,280 shares, through it's At the Market (ATM) offering agreement with H.C. Wainwright & Co. Following the reported sale of these ADSs, Addex's cash runway has been extended to the fourth quarter of 2027. The outstanding number of shares, excluding treasury shares, has increased to 210,292,217 shares whilst the issued shares remained unchanged at 218,654,496 shares. About Addex Therapeutics: Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex holds a 20% equity interest in a private spin out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders and mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange. For more information, visit www.addextherapeutics.com. Contacts: | Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 [email protected] | Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 [email protected] | Addex Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

BizWire Express
Aug 3rd, 2026
BizWire Express > - Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

BizWire Express - Bringing you the latest news as it happens from all over the world.